Outlook Therapeutics closes $60M private placement and effects 1-for-20 reverse stock split

Outlook Therapeutics, Inc.

Private placement raised ~$60M via 8.57M shares at $7.00 each plus warrants for 12.86M shares at $7.70.
Warrants expire March 18, 2029; exercise price $7.70 per share.
1-for-20 reverse stock split effective March 13, 2024; authorized shares reduced to 60M.
After split and before placement, ~13.0M shares outstanding; securities sold under Rule 506 exemption.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Outlook Therapeutics, Inc.: Effected a 1-for-20 reverse stock split and proportionate reduction in authorized shares of Common Stock via Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-03-13).

Change: charter amendment
Effective: 2024-03-13

Exact text from the filing

Effective March 13, 2024 at 5:00 p.m. Eastern Time, the Company effected a 1-for-20 reverse stock split and proportionate reduction in the number of authorized shares of Common Stock pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-035644

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.